Synthesis and Characterization of Zinc Oxide and Zinc Oxide Doped with Chlorine Nanoparticles as Novel α-Amylase Inhibitors ()
1. Introduction
Zinc oxide nanoparticles (ZnONPs) was an important functional oxide because it is a cheap non-toxic semiconductor and has a wide (Eg~3.37 ev) direct band gab, with a large (60 mev) excitonic binding energy. Zinc oxide (ZnO) has greatly influenced the properties through its growth process, particle size, and especially through morphology [1] [2]. Additionally, ZnO is primarily used as products of personal care, electronics, chemical sensors, solar energy conversion, various luminescence, photo-catalysis and other applications such as sunscreens, which require UV protection, so ZnO is considered the most common types of metal used in the preparation of NP [3] [4] [5] [6]. Different substrates such as Al2O3, silica, carbon and SiO2 are usually deposited with ZnO to improve its utilization. For example, activated carbon mixtures and ZnO [7] [8] [9] [10], are usually used to obtain ZnO/carbon composites by solution combustion of a single step synthesis [11], and used as an electrode for photocatalytic catalyst and supercapacitor of electrochemical [7] [11]. Also, it can enter the environment via domestic sewage from swimming or showering or through wastewater at industrial sites. Sewage sludge is used (e.g. fertilizer) for land application; it can be used for transporting NP to soil.
In recent days, it was found that ZnO nano-crystallites properties were dramatically changed by surface coating with different semiconductors [12]. Generally, the core-shell structured material synthesis leads to obtain a new composite material having properties between the shell and core materials [13] [14] [15]. One of the potential applications as electroluminescent devices and candidates for the coating materials [16] is ZnS (Zinc sulfide) that has 3.72 eV wide band gap [17]. Gonzalez-Hernandeza et al. [18] prepared ZnO nanoparticles doped with fluorine by the precipitation technique and reported the yields of F:ZnO and ZnO. Nano-arrangements consist of different lengths of nanoparticles with ~30 nm chains in size and quasi-spherical in shape. One of the major digestive enzymes in animals is α-amylases, which work on the polysaccharides and break them into small chains (such as starch, the major sugar in the diet, broken by α-amylases into glucose and maltose). When inhibiting α-amylases, there will be less sugar available for assimilation and thus easier to control diabetes. Therefore, α-amylase is used in the design of drugs and the development of compounds used in treatment of obesity, hyperlipidemia and diabetes [19]. When using ZnO nanoparticles to inhibit the α-amylase activity for the first time, it was found that 20 µg/ml optimum dose was sufficient to inhibit 49% of glucose at 35˚C and neutral pH. Inhibition by ZnO nanoparticles is similar to inhibition obtained by acarbose (standard of α-amylase inhibitor), so increment of the production of ZnO nanoparticles is very important as a novel type of amylase inhibitor. Recently, it has been shown that ZnO nanoparticles have function as an active material for bio applications [20] [21] [22] [23] [24] typically as cholesterol biosensors, dietary modulators for hydrolase’s activity and antimicrobial agents, due to its high surface to volume ratio [25]. When comparing the precipitation approach method with other traditional methods provides a facile way for large-scale production and low cost, which does not need complicated equipment and expensive raw materials [26], the ability to prepare compounds with varying morphologies having different properties, nontoxicity, existentially found in nature [27]. Therefore, the present study aimed to: 1) synthesize the highly pure ZnONPs and Cl:ZnONPs at different conditions by precipitation technique; 2) examine the antidiabetic activity of ZnONPs and Cl:ZnONPs.
2. Experiment
2.1. Samples Preparation
The method of chemical solution from oxalic acid (OX. acid) and zinc acetate (ZnAc) was used to prepare ZnO nanoparticles doped with chlorine and ZnO nanoparticles. Added OX. acid 0.5 M ethanolic solution (20 mL) drop-by-drop under stirring to ZnAc 0.1 M ethanolic solution (20 mL) and maintained for 1 h and 2 h to prepare (sample: a, b, c, d) at 60˚C. Added to the above solution, ammonium chloride aqueous solution (0.5 M) in order to obtain the ratio of Cl/Zn at 5% to prepare (sample: b and d). A white precipitate was obtained for all samples. Filtrated the samples to separate the precipitates, then washed them by water : ethanol (75:25) mixture. An oven was used to dry the precipitate for 24 h at 100˚C. Finally calcined the obtained precursor for 2 h at 500˚C, with 5˚C/min to prepare ZnO nanoparticles doped with Cl− (sample: e), added OX. acid 0.5 M ethanolic solution (20 mL) drop-by-drop under stirring to ZnAc 0.1 M ethanolic solution (20 mL) and maintained for 1 h at 60˚C [18].
2.2. Samples Characterization
Fourier Transform Infrared Spectrometer (FTIR) was used to analyze the structure of the samples and IRAFFINITY-1 Shimadzu’s in KBr pellets to recorder them in the range of 4000 - 400 cm−1. The crystallinity was assessed by X-ray powder diffractometer (D/max r-B, Rigaku, Japan). Scanning Electron Microscopy (SEM) (Czec Republic, FEI, ISPECT S50) with 20 kV accelerating voltage and Transmutation Electron Microscopy (TEM) (Czec Republic, FEI, TEM) with 80 kV accelerating voltage were used to analyze the Morphology of Surface.
2.3. α-Amylase Inhibitory Assay
The activity of α-amylase inhibitory assayed by the method was described by [28].
3. Results and Discussion
All prepared samples’ IR spectra were shown in Figure 1. The H–O–H bending vibration and stretching modes were shown at 1650 cm−1 and 3500 broad bands of the absorbed or free water. The band observed at 1260 cm−1 is attributed to (C-O) + (O-C=O) of –COOH groups of oxalic acid. Strong absorptions at 470 cm−1 indicate that the ZnO cluster is formed. Zinc oxide characteristic distinct stretching vibration was shown at 470 cm−1. The hydroxyl group characteristic absorption was indicating at 3400 cm−1 broad absorption peak [29]. Moreover, absorption peak of undoped ZnO was observed at 372 nm (3.33 eV), this result agrees with the results reported by Ansari NH et al. [30] for ZnO single crystals.
All prepared samples X-ray diffraction (XRD) patterns are shown in Figure 2. All Samples exhibited similar patterns indicating high crystallinity. The positioned of diffraction peaks at 2θ values = 31.1˚, 34.4˚, 36˚, 47.1˚, and 56.6˚ were indicated, which correspond to ZnO planes ((100), (002), (101), (102), and (110)), respectively [4]. Also, this result agrees with the diffraction peaks reported by [4] for zinc oxide hexagonal wurtzite phase in JCPDS card no. 36-1451. From our results, also no other diffraction peaks were noted, therefore, the prepared ZnO are of the pure wurtzite phase. 2θ values of the diffraction peaks which recorded of ZnO = (31.9˚), (34.6˚), (36.4˚), (47.7˚), (56.7˚), (62.9˚), and (68.10), which correspond to diffraction planes: (100), (002), (101), (102), (103), (112) and (201), respectively. It can index these diffraction planes to Zinc and its structure zinc oxide (ZnO) indicating its crystallinity is high [3]. The wurtzite ZnO structure matches very well with all the diffraction peaks (JCPDS card No. 891397), which shows the diffraction peaks as lines in the figure lower side. By using Scherrer’s equation, the product exhibits good crystallinity because it has strong diffraction peaks [2].
Figure 2. X-ray patterns of: (a) ZnONPs at 1 h, (b) Cl:ZnONPs at 1 h, (c) ZnONPs at 2 h, (d) Cl:ZnONPs at 2 h and (e) Cl:ZnONPs at 1 h.
where:
Dp = size of Average Crystallite, θ = Bragg angle, λ = X-ray wavelength for the more intense peaks, β = Line broadening in radians.
Figure 3, Figure 4 show the morphological characteristics of the ZnONPs and ZnONPs powders prepared with chlorine doping revealed by SEM. ZnONPs at 1 and 2 h (Figure 3(a) and Figure 3(c)), also Cl:ZnONPs (Figure 3(b)) at 1 h show a round shape. On the other hand, Cl:ZnONPs at 2 h (d) and Cl:ZnONPs at 1 h (e) show rode shape. The synthesized nanoparticles have average size 46.65 - 74.64 nm. These results agree with Abd El-Rahman et al. [29]. They reported that Cl:ZnONPs show a round shape. The shape difference may be due to the doping nature, the synthesized nanoparticles size is 40 - 50 nm in the range and is nearly spherical in shape. In addition, the particle size determined from analysis of SEM is in good agreement with that of the XRD analysis [29].
Figure 5 (sample a and c) shows ZnO nanoparticles have around 30 nm in round shaped, the amplification in the inset shows that the most particles in the chains are arranged of a length of ~1 μm and other particles are agglomerated. The (samples b, d and e) in Figure 5 shows the Cl:ZnO nanoparticles TEM images. The prepared powders of ZnO nanoparticles have particle size about 59.3 nm [29]. The analysis of TEM indicated that the ZnONPs particle size varies between 14 and 27 nm, depending on the nanoparticles synthesis method. The ZnONPs morphological characteristics revealed by TEM showed nanocrystalline particles presence and aggregation with various sizes and shapes [31]. Gonzalez-Hernandez, et al. [18] reported that Cl:ZnO and ZnONPs have 22 nm and 30 nm particle size, respectively.
The α-amylase inhibitory activity of ZnONPs and Cl:ZnONPs (a-e) at varies concentration from (7.81 to 1000 µM) was studied, Table 1 and Figure 6 show the results obtained. The results exhibited a good significant inhibitory activity against α-amylase enzyme of compounds a-c and d when comparable with that of acarbose. Compound (a) showed highly significant inhibition activity (38.11 ± 1.33 and 88.32 ± 0.73)% inhibition at (7.81 and 1000) µM/l concentration, respectively IC50 = 25.54. Compound (c) and (d) showed (37.11 ± 1.2, 30.11 ± 1.38), (42.25 ± 1.5, 35.25 ± 1.22), (47.16 ± 0.63, 45.16 ± 0.53), (59.46 ± 0.58, 53.46 ± 0.68), (63.78 ± 1.2, 59.78 ± 1.29), (69.24 ± 1.5, 61.24 ± 1.56), (76.14 ± 0.63, 69.14 ± 0.69) and (85.32 ± 0.72, 76.32 ± 0.78)% inhibition at (7.81 to 1000) µM/l concentration, respectively, IC50 = (38.47, 49.47) for compound c and d, respectively. Our results agree with Dhobale et al. (2008) [32] they reported that; when used ZnO nanoparticles to inhibit the α-amylase activity at the first time, it found that 20 µg/ml optimum dose was sufficient to inhibit 49% of glucose [32].
Figure 3. Last two-specimens of low and high magnification SEM images: (a) ZnONPs at 1 h, (b) Cl:ZnONPs at 1 h, (c) ZnONPs at 2 h, (d) Cl:ZnONPs at 2 h and (e) Cl:ZnONPs at 1 h. The surface morphology of the particles is clearly visible at high magnification micrographs. All scale bars correspond to 3 µm (right column).
Figure 4. Last two-specimens of low and high magnification SEM images: (a) ZnONPs at 1 h, (b) Cl:ZnONPs at 1 h, (c) ZnONPs at 2 h, (d) Cl:ZnONPs at 2 h and (e) Cl:ZnONPs at 1 h. The surface morphology of the particles is clearly visible at high magnification micrographs. All scale bars correspond to 3 µm (right column).
Figure 5. The images of TEM: (a) ZnONPs at 1 h, (b) Cl:ZnONPs at 1 h, (c) ZnONPs at 2 h, (d) Cl:ZnONPs at 2 h and (e) Cl:ZnONPs at 1 h. The surface morphology of the particles is clearly visible at high magnification micrographs. All scale bars correspond to 3 µm (right column).
Table 1. Anti-diabetic activity is depicted in the ZnONPs and Cl:ZnONPs.
Figure 6. α-Amylase inhibitory assay test for (a) ZnONPs at 1 h, (b) Cl:ZnONPs at 1 h, (c) ZnONPs at 2 h, (d) Cl:ZnONPs at 2 h and (e) Cl:ZnONPs at 1 h.
4. Conclusion
ZnONPs and Cl:ZnONPs were elucidated as α-amylase inhibitors. Compound (c) shows the best inhibitory activity than other compounds except compound (a) when compared with the standard of α-amylase (acarbose). Moreover, compound (a) gives the highest inhibitor activity than acarbose. So we concluded that the present results, considered as beginning to pave the way to identify a new material (Cl:ZnONPs), can be used in the treatment of chronic diseases such as diabetes in the field of biomedicine.
Acknowledgements
The author extends their sincere thanks to the Institute for Research and Medical Consultations (IRMC) and research units of Science College in Imam Abdulrahman Bin Faisal University.